论文部分内容阅读
目的:评价贝伐珠单抗与吉西他宾联用对晚期宫颈腺癌患者的临床疗效及安全性。方法:选取2013年1月—2014年6月治疗的晚期宫颈腺癌患者160例为对象,将其分为吉西他宾组和联用组,各80例;吉西他宾组患者接受吉西他宾单药化疗,联用组患者在此基础上辅以贝伐珠单抗化疗;评价两组患者治疗后的疗效和安全性。结果:联用组患者治疗后CER、DCR均明显高于吉西他宾组(P<0.05);联用组患者ADR的发生率明显低于吉西他宾组(P<0.05)。结论:贝伐珠单抗与吉西他宾联用化疗对晚期宫颈腺癌患者的临床疗效优于单纯化疗。
Objective: To evaluate the clinical efficacy and safety of bevacizumab in combination with gemcitabine for patients with advanced cervical adenocarcinoma. Methods: One hundred and sixty patients with advanced cervical adenocarcinoma treated from January 2013 to June 2014 were enrolled in this study. They were divided into gemcitabine group and combination group, 80 cases in each. Gemcitabine group received Western medicine single-agent chemotherapy, combination group patients on this basis supplemented with bevacizumab chemotherapy; evaluation of two groups of patients after treatment efficacy and safety. Results: After treatment, the combined therapy group had significantly higher CER and DCR than gemcitabine group (P <0.05). The incidence of ADR in combination group was significantly lower than that in gemcitabine group (P <0.05). Conclusion: The combination of bevacizumab and gemcitabine is more effective than chemotherapy in patients with advanced cervical adenocarcinoma.